QuantHealth, an AI-enabled clinical trial design company, has announced that it has secured $15 million in a Series A funding round. The funding was co-led Pitango HealthTech and Bertelsmann Investments, bringing the total amount raised QuantHealth to $20 million.
The Israeli-based company offers its AI-powered Clinical-Simulator, which predicts an individual’s response to treatment during a clinical trial. This technology optimizes clinical trial design, ultimately saving pharmaceutical companies millions of dollars and helping them bring drugs to market more quickly. With the additional funding, QuantHealth plans to further develop its product, expand its platform, and explore new use cases beyond clinical trials, including early research and development and regulatory support.
“We are very pleased to co-invest in QuantHealth alongside Pitango and to further expand our growth unit Bertelsmann Next with an investment focus on Digital Health,” said Thorsten Wirkes of Bertelsmann Investments. “The impressive AI technologies of QuantHealth have proven to save pharmaceutical companies millions, helping them bring drugs to market quicker and get patients the treatments they need.”
In other funding news, Oklahoma-based medication management platform PatchRx has raised $8 million in Series A funding, bringing its total raise to $15 million. The funding round was led Atento Capital, with participation from Cortado Ventures, Vast Ventures, Plains VC, and Forum Ventures.
PatchRx offers a smart pill bottle that uses data to enhance medication adherence. With the new funds, the company plans to expand its footprint nationally, providing more patients with access to its innovative medication management technology.
Finally, Singapore-based Neurpowyzer has raised an additional $2.1 million in its oversubscribed seed round, bringing the total amount raised to $3.3 million. The funding round was co-led Jungle Ventures and Peak XV’s Surge, with participation from angel investors.
Neurpowyzer focuses on brain health and mitigating brain decline using technology. The company has developed an online digital assessment called the Digital Brain Function Screen, which evaluates the potential of early brain decline. This assessment tests immediate memory, working memory, attention, and executive function. The seed funding will be used to support the company’s product development and expand its presence across Southeast Asia and India.
Overall, these funding announcements indicate the growing investment in companies leveraging AI and technology to improve healthcare outcomes and advance patient care.
– Funding for AI-enabled clinical trial design company QuantHealth reaches $15m
– PatchRx Raises $8M Series A for Smart Pill Bottle Expansion Effort
– Brain health tech firm Neurpowyzer adds $2.1m to seed round